In addition, there are now 5 aflibercept biosimilars approved in the US, 3 of which have been granted the interchangeability designation: Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis ...

But let me just say a word on Wyost/Jubbonti and Enzeevu. Last year, we launched Wyost/Jubbonti or biosimilar denosumab in Canada, and we're looking forward to the launch in the U.S. in the coming ...

Similarly, the company gave no definitive schedule for the U.S. rollout of Tyruko and Enzeevu. "This lack of a precise timing along with concerns related to tariffs should keep investors at bay for ...

Similarly, the company gave no definitive schedule for the U.S. rollout of Tyruko and Enzeevu. "This lack of a precise timing along with concerns related to tariffs should keep investors at bay ...

Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and ...

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop ...

Imminent U.S. launch of Wyost/Jubbonti (denosumab) with European launch in Q4 2025 2. Enzeevu/Afqlir (aflibercept) launch in Europe in Q4 2025 3. Tyruko (natalizumab) launch in the U.S. by the end of ...